Hir­ing? How End­points can help your com­pa­ny fill open po­si­tions with our tal­ent­ed read­ers

We’ve just launched End­points Ca­reers, our new prod­uct con­nect­ing em­ploy­ers and job­seek­ers. The com­pe­ti­tion for bio­phar­ma tal­ent is fierce, and giv­en the unique place End­points News has in the in­dus­try, we think our ap­proach has a few key ad­van­tages that make this a com­pelling of­fer and not just an­oth­er “job board.”

The first rea­son is that we’re an­chor­ing it to En­ter­prise, our $1,000/year paid sub­scrip­tion plan for com­pa­nies of all sizes. You can think of En­ter­prise as the “com­plete” ver­sion of End­points News. No mat­ter how large or small the com­pa­ny is, that one price un­locks pay­wall con­tent for every em­ploy­ee. No seat li­cens­es or vol­ume pric­ing. We want to make this pro­gram an easy de­ci­sion at every com­pa­ny with an in­ter­est in the bio­phar­ma world. Sev­er­al hun­dred have al­ready joined En­ter­prise, and now with End­points Ca­reers, we want to make it even more ben­e­fi­cial to join.

Start­ing to­day, we’re in­tro­duc­ing a new ben­e­fit for En­ter­prise sub­scribers: Two Fea­tured Job List­ings per year on End­points Ca­reers — an $800 val­ue. If you’re a hir­ing man­ag­er at a com­pa­ny with a valid En­ter­prise sub­scrip­tion, you have two fea­tured job post­ings wait­ing for you to re­deem — just con­tact Tom Kowal­sky tom@end­pointsnews.com on our team to get start­ed. And once you do, the list­ings will be dis­trib­uted across the en­tire End­points net­work: email, web, and so­cial. Again: we’re sell­ing the same pack­age for $800 for com­pa­nies who aren’t part of the En­ter­prise pro­gram.

The oth­er key ad­van­tage on End­points Ca­reers is our fo­cus on qual­i­ty, not quan­ti­ty.

Most “job boards” be­gin with thou­sands of job list­ings pre-filled, in an at­tempt to look busy and gain web traf­fic. We take the op­po­site view. We on­ly want re­cent jobs with the high­est rel­e­vance to our au­di­ence base. And giv­en the big traf­fic num­bers to End­points News and our re­lat­ed dis­tri­b­u­tion chan­nels, we’re able to ad­ver­tise these po­si­tions in a very ef­fec­tive way: Job seek­ers are as­sured of see­ing on­ly the high­est qual­i­ty list­ings from em­ploy­ers, while em­ploy­ers get wide air cov­er­age for their open po­si­tions with­in the elite End­points read­er­ship.

We de­signed it this way. Bio­phar­ma tends to be an in­su­lar crowd with an es­pe­cial­ly big pre­mi­um placed on re­fer­rals from in­side a net­work — which is no sur­prise in an in­dus­try that is as heav­i­ly reg­u­lat­ed and sci­ence-based as this one is. In­sti­tu­tion­al knowl­edge is held by peo­ple, not in com­pa­ny clouds or lab notes. And the net­work ef­fects gained from re­cruit­ing the right kind of ex­pe­ri­enced tal­ent who know the right peo­ple are too valu­able to be mea­sured in dol­lars. This won’t ever change. It’s a sto­ry we chron­i­cle in End­points about every com­pa­ny with am­bi­tion, time and time again.

But re­fer­rals do have their lim­its. Was the job op­por­tu­ni­ty ex­posed to the most di­verse tal­ent pool pos­si­ble? How does a found­ing team of a few fa­mil­iar faces re­cruit a work­force that can bring fresh ideas and ap­proach­es?

Ba­si­cal­ly: Did we cast a wide enough net?

End­points Ca­reers is here to help solve this is­sue: ad­ver­tis­ing bio­phar­ma op­por­tu­ni­ties with­in an elite net­work, and do­ing so on a scale that ex­pos­es it to the broad­est au­di­ence pos­si­ble.

We think that’s a com­pelling of­fer that con­tin­ues to dif­fer­en­ti­ate End­points and how we serve our read­ers. End­points Ca­reers will on­ly con­tin­ue to grow through­out the year as we in­te­grate it with our week­ly Peer Re­view col­umn. If you have any ques­tions or want to get start­ed with End­points Ca­reers, we’ve brought Tom tom@end­pointsnews.comon board as a ded­i­cat­ed client man­ag­er to help, and you can al­ways con­tact me di­rect­ly as well. So please check out End­points Ca­reers — we’re very ex­cit­ed to bring it to you.

– Ar­salan Arif
Founder & CEO, End­points News
aa@end­pointsnews.com

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

VCs love few things more than a proven executive team when it comes to launching a new company. And now a group of A-listers has turned to a pair of top execs out of AveXis to steer the latest gene therapy player into the clinic.

The biotech is Waltham, MA-based Affinia and the two execs are Sean Nolan and Rick Modi — the former CEO and CBO respectively of AveXis, the gene therapy pioneer that fetched $8.7 billion in a sale to Novartis. Nolan has now taken the chairman’s role at Affinia while Modi moves up to the CEO post at the company.

Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

When Pieter van der Meer started raising the capital for Gilde Healthcare’s fifth fund in the waning months of 2019, he had his eyes on a different chain of events that could change the healthcare system and perhaps even play to his firm’s advantage: The US presidential election.

Since raising their third fund in 2011, the 34-year-old Dutch firm had focused on value-based care. They chose late-stage biotechs that came up with new devices and delivery systems for de-risked established compounds, and when they chose preclinical biotechs, they spoke with potential pharma partners, payers and regulators to ask where and at what prices the drug made sense. As the Democratic primary became a contest over how to lower healthcare costs, it looked like a strategy that could pay off.

Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

A new CAR-T therapy may be coming. And maybe $9 per share for Celgene investors, too.

Bristol Myers Squibb announced they submitted an NDA for the multiple myeloma “ide-cel” CAR-T therapy Celgene developed in partnership with bluebird. The therapy is one of the three that has to be approved to unlock the BMS-Celgene contingent value agreement that would give shareholders of the absorbed NJ company $9 per share. The first, ozanimod, was approved last week. The second, a CAR-T treatment for non-Hodgkin’s lymphoma called liso-cel, was submitted to the FDA in December.

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of piv­otal da­ta

J&J has zeroed in on a Covid-19 vaccine candidate that it hopes to begin testing in humans by September this year — with the extraordinary goal of getting it ready for emergency use in early 2021. And together with BARDA, it’s committing $1 billion to make it happen.

That kind of accelerated timeline would fall on the fast side of NIAID director Anthony Fauci’s well-publicized prediction that it would be another 12 to 18 months before a vaccine can be available for public use. A Phase I trial of Moderna’s mRNA vaccine began two weeks ago, and both the biotech and fellow mRNA player CureVac have discussed similar, if not even faster, timelines for emergency use among healthcare workers.

Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Daniel O'Day (AP Images)

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

After coming under heavy fire from consumer groups ready to pummel them for grabbing the FDA’s orphan status for remdesivir — reserved to encourage the development of rare disease therapies — Gilead CEO Daniel O’Day had some explaining to do about the company’s approach to providing access to this drug to patients suffering from Covid-19. And he set aside time over the weekend to patiently explain how they are making their potential pandemic drug available in a new program — one he feels can better be used to address a growing pack of infected patients desperately seeking remdesivir under compassionate use provisions.

In addition to trying to reassure patients that they will once again have an avenue to pursue access, O’Day also reassured some analysts who had been fretting that China’s quick comeback from the coronavirus outbreak could derail its ultra-fast schedule for testing the drug in patients. The data are still expected in a few weeks, he says in the letter, putting the readout in April.

O’Day emphasizes that Gilead intends to pursue a pricing approach that will make this drug widely available — if it proves effective and safe. But no one is quite sure just what the longterm value would be, given the work being done on a variety of vaccines that may be rolled out as early as this fall — at least to the most heavily threatened groups.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.